Arcturus Therapeutics (ARCT) to Release Quarterly Earnings on Wednesday

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.69) by $1.37. The business had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

Shares of ARCT stock opened at $27.27 on Monday. The business has a 50-day simple moving average of $32.74 and a 200-day simple moving average of $30.02. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $43.81.

Analysts Set New Price Targets

ARCT has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Citigroup upped their price target on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.33.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total transaction of $299,860.65. Following the completion of the transaction, the chief operating officer now owns 490,883 shares of the company’s stock, valued at $17,185,813.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.